gms | German Medical Science

28. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

24. bis 27.11.2004, Hannover

Anti-inflammatory effects of angiotensin II subtype 1-receptor blockade in hypertensive patients with micro-inflammation

Meeting Abstract (Hypertonie 2004)

Suche in Medline nach

  • D. Fliser - Medizinische Hochschule Hannover (Hannover, D)
  • H. Haller - Medizinische Hochschule Hannover (Hannover, D)

Hypertonie 2004. 28. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Hannover, 24.-27.11.2004. Düsseldorf, Köln: German Medical Science; 2005. Doc04hochP77

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hoch2004/04hoch077.shtml

Veröffentlicht: 10. August 2005

© 2005 Fliser et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: Experimental studies revealed pro-inflammatory properties of angiotensin II. We evaluated anti-inflammatory effects of the angiotensin II subtype 1-receptor antagonist olmesartan medoxomil alone and in co-therapy with the HMG-CoA-reductase-inhibitor pravastatin in patients with essential hypertension and micro-inflammation.

Methods and Results: We measured a panel of vascular inflammation markers including high-sensitivity C-reactive protein (hsCRP) and lipid levels during 12 weeks of therapy with olmesartan (n = 100) or placebo (n = 99) in a prospective double-blind multi-center study. Pravastatin was added to the double-blind therapy at week 6 in both treatment arms. Blood pressure control was achieved with addition of hydrochlorothiazide. Olmesartan treatment significantly reduced serum levels of hsCRP (-15.1%; p<0.05), high-sensitivity tumor necrosis factor-Ą (hsTNF-Ą; -8.9%; p<0.02), interleukin-6 (IL-6; -14.0%; p<0.05) and monocyte chemotactic protein-1 (MCP-1; -6.5%; p<0.01) already after 6 weeks of therapy, whereas placebo treatment (i.e. blood pressure reduction) had no major effect on inflammation markers. After 12 weeks of therapy hsCRP (-21.1%; p<0.02), hsTNF-Ą (-13.6%; p<0.01) and IL-6 (-18.0%; p<0.01) decreased further with olmesartan and pravastatin co-therapy, but treatment with pravastatin alone (i.e. co-therapy with placebo) did not significantly alter inflammation markers. In contrast, addition of pravastatin lead to a significant reduction (p<0.001) of low-density lipoprotein cholesterol serum concentrations in the olmesartan and placebo treatment group (-15.1% and -12.1% respectively).

Conclusions: Angiotensin II-receptor blockade significantly reduces vascular micro-inflammation in patients with essential hypertension already after 6 weeks of therapy. This anti-inflammatory action of angiotensin II-receptor antagonists may contribute to their beneficial cardiovascular effects.